Erectile dysfunction (ED) is a common condition characterized by the inability to achieve or maintain an erection sufficient for sexual activity. The first-line treatment for ED includes oral phosphodiesterase type 5 inhibitors (PDE5i) such as sildenafil and tadalafil. However, there remains a significant unmet clinical need for more effective therapies due to the limitations of current treatments, including side effects and contraindications. As ED prevalence is expected to reach 322 million men by 2025, the growing focus on novel erectile dysfunction therapeutic products is likely to support pipeline expansion.
Major companies involved in the erectile dysfunction pipeline drugs market include Vigonvita Life Sciences, Dicot AB, and others.
Leading drugs currently in the pipeline include Testofen, LIB-01, and others.
The growth of the erectile dysfunction drug pipeline is driven by the rising global prevalence of ED, increasing demand for more effective and safer therapies, and ongoing advancements in innovative drug formulations and treatment approaches.
The Erectile Dysfunction Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into erectile dysfunction therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for erectile dysfunction. The erectile dysfunction report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The erectile dysfunction pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with erectile dysfunction treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to erectile dysfunction.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Erectile dysfunction, also known as impotence, is a common condition where a man is unable to achieve or maintain an erection adequate for sexual activity. It can be caused by various physical factors, such as diabetes, cardiovascular disease, or hormonal imbalances, as well as psychological causes such as stress, anxiety, and depression. Lifestyle choices, including smoking or poor diet, can also contribute to its prevalence.
Erectile dysfunction treatment typically includes medications like PDE5 inhibitors, which help improve blood flow to the penis. Other treatments may involve lifestyle changes such as regular exercise, weight loss, and reducing alcohol consumption. Psychological therapy may address anxiety or depression. Hormone therapy, penile injections, and surgical methods such as penile implants are available for more severe cases.
Erectile dysfunction is a prevalent condition with a significant global impact. By 2025, an estimated 322 million men will be affected. In the United States, over 18 million men, or 18.4% of the male population aged 20 and older, suffer from erectile dysfunction. Prevalence is high among diabetic patients, ranging from 35% to 90%. It affects up to 1 in 5 men in the United Kingdom and approximately 34.5% of men in Japan. In India, erectile dysfunction impacts 1 in 10 men, with a rising incidence in younger individuals.
This section of the report covers the analysis of erectile dysfunction drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total erectile dysfunction clinical trials.
The drug molecule categories covered under the erectile dysfunction pipeline analysis include small molecules, peptides, proteins, gene therapies, stem cells, and others. The erectile dysfunction report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for erectile dysfunction.
The EMR report for the erectile dysfunction drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed erectile dysfunction therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in erectile dysfunction clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for erectile dysfunction. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of erectile dysfunction drug candidates.
Testofen, a natural supplement derived from fenugreek seed extract, is being evaluated in a Phase III clinical trial sponsored by RDC Clinical Pty Ltd. The study aims to assess its impact on erectile function, sexual performance, and quality of life in adult males. This double-blind, randomized, placebo-controlled trial includes two active groups (300 mg and 600 mg doses) and a placebo group.
LIB-01, a novel small molecule and first-in-class analogue, is derived from a root bark traditionally used in ethnopharmacology. This investigational drug candidate is part of a Phase II trial, sponsored by Dicot AB, which aims to assess the efficacy and safety of LIB-01 in treating erectile dysfunction. This study will compare LIB-01 to a placebo to evaluate its impact on erectile function and any potential side effects.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Erectile Dysfunction Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for erectile dysfunction. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into erectile dysfunction collaborations, regulatory environments, and potential growth opportunities.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share